Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Wolfe Research Boosts Merck Price Target to $180 After Positive Cancer Treatment Trial

Guavy AI Editorial Team
Instruments
MRK
Share

Wolfe Research has raised its price target for Merck & Co. (NYSE:MRK) to $180 from $155, maintaining an Outperform rating following positive trial results for the company's cancer treatment combination.

The analyst expects earnings stability ahead of Keytruda's patent expiry in 2029 and projects that Merck's earnings will remain relatively flat in 2028 and 2029 at $8.89 and $8.79 per share, respectively.

Merck and partner Moderna (NASDAQ:MRNA) reported a positive outcome for INTerpath-001, a trial combining intismeran with Keytruda. Intismeran is administered intramuscularly, and Wolfe Research noted the Keytruda QLEX injection formulation could reduce patient burden when used in combination.

More on Stocks

Stocks just now

NSA's Secret Cold War Computer Was a Speed Demon

Stocks 1m ago

NVIDIA Named Top Tech Stock Amid Industry Leadership

Stocks 1m ago

Nvidia Supplies Vera CPUs for SpaceXAI's Ambitious AI Infrastructure Project

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy